Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Yubo International Biotech Q3 2026 Results: Net Loss of $188K, Loss Narrows

Yubo International Biotech Ltd is a U.S. holding company operating in China through a Variable Interest Entity (VIE) structure focused on stem cell research and development. As of September 30, 2026, the company reported total cash of $9,465 and is classified as a non-accelerated filer and smaller reporting company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Gross profit0.00.0
Profit before tax-0.2-0.3
Net income-0.2-0.3
EPS (diluted, $ a share)$0.00$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: YBGJ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Yubo International Biotech Ltd: key numbers

Share price
$0.0055Close, Nov 16
Market cap
$937K
Shares outstanding
170.42MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.